These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 20187348)

  • 1. Effect of oral antihistamine on local injection site reactions with self-administered glatiramer acetate.
    Pardo G; Boutwell C; Conner J; Denney D; Oleen-Burkey M
    J Neurosci Nurs; 2010 Feb; 42(1):40-6. PubMed ID: 20187348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate.
    Jolly H; Simpson K; Bishop B; Hunter H; Newell C; Denney D; Oleen-Burkey M
    J Neurosci Nurs; 2008 Aug; 40(4):232-9. PubMed ID: 18727339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tolerability and safety of novel half milliliter formulation of glatiramer acetate for subcutaneous injection: an open-label, multicenter, randomized comparative study.
    Anderson G; Meyer D; Herrman CE; Sheppard C; Murray R; Fox EJ; Mathena J; Conner J; Buck PO
    J Neurol; 2010 Nov; 257(11):1917-23. PubMed ID: 20953791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis.
    Fox RJ; Miller DH; Phillips JT; Hutchinson M; Havrdova E; Kita M; Yang M; Raghupathi K; Novas M; Sweetser MT; Viglietta V; Dawson KT;
    N Engl J Med; 2012 Sep; 367(12):1087-97. PubMed ID: 22992072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Localized panniculitis and subsequent lipoatrophy with subcutaneous glatiramer acetate (Copaxone) injection for the treatment of multiple sclerosis.
    Soós N; Shakery K; Mrowietz U
    Am J Clin Dermatol; 2004; 5(5):357-9. PubMed ID: 15554737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases.
    Ball NJ; Cowan BJ; Moore GR; Hashimoto SA
    J Cutan Pathol; 2008 Apr; 35(4):407-10. PubMed ID: 18333902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial.
    Comi G; Martinelli V; Rodegher M; Moiola L; Bajenaru O; Carra A; Elovaara I; Fazekas F; Hartung HP; Hillert J; King J; Komoly S; Lubetzki C; Montalban X; Myhr KM; Ravnborg M; Rieckmann P; Wynn D; Young C; Filippi M;
    Lancet; 2009 Oct; 374(9700):1503-11. PubMed ID: 19815268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GLACIER: An open-label, randomized, multicenter study to assess the safety and tolerability of glatiramer acetate 40 mg three-times weekly versus 20 mg daily in patients with relapsing-remitting multiple sclerosis.
    Wolinsky JS; Borresen TE; Dietrich DW; Wynn D; Sidi Y; Steinerman JR; Knappertz V; Kolodny S;
    Mult Scler Relat Disord; 2015 Jul; 4(4):370-6. PubMed ID: 26195058
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential glatiramer acetate treatment persistence in treatment-naive patients compared to patients previously treated with interferon.
    Fernández-Fournier M; Tallón-Barranco A; Chamorro B; Martínez-Sánchez P; Puertas I
    BMC Neurol; 2015 Aug; 15():141. PubMed ID: 26286576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contact dermatitis induced by glatiramer acetate.
    Haltmeier S; Yildiz M; Müller S; Anliker MD; Heinzerling L
    Mult Scler; 2011 Nov; 17(11):1390-2. PubMed ID: 21729979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with glatiramer acetate for multiple sclerosis.
    Munari L; Lovati R; Boiko A
    Cochrane Database Syst Rev; 2004; (1):CD004678. PubMed ID: 14974077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
    Cohen J; Belova A; Selmaj K; Wolf C; Sormani MP; Oberyé J; van den Tweel E; Mulder R; Koper N; Voortman G; Barkhof F;
    JAMA Neurol; 2015 Dec; 72(12):1433-41. PubMed ID: 26458034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].
    Boyko AN; Alifirova VM
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(11):135-139. PubMed ID: 29265099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefit of endermology on indurations and panniculitis/lipoatrophy during relapsing-remitting multiple sclerosis long-term treatment with glatiramer acetate.
    Márquez-Rebollo C; Vergara-Carrasco L; Díaz-Navarro R; Rubio-Fernández D; Francoli-Martínez P; Sánchez-De la Rosa R
    Adv Ther; 2014 Aug; 31(8):904-14. PubMed ID: 25047757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
    Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
    Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study.
    Filippi M; Wolinsky JS; Comi G;
    Lancet Neurol; 2006 Mar; 5(3):213-20. PubMed ID: 16488376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spotlight on glatiramer acetate in relapsing-remitting multiple sclerosis.
    Simpson D; Noble S; Perry C
    BioDrugs; 2003; 17(3):207-10. PubMed ID: 12749757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group.
    Johnson KP; Brooks BR; Ford CC; Goodman A; Guarnaccia J; Lisak RP; Myers LW; Panitch HS; Pruitt A; Rose JW; Kachuck N; Wolinsky JS
    Mult Scler; 2000 Aug; 6(4):255-66. PubMed ID: 10962546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contribution of endermology to improving indurations and panniculitis/lipoatrophy at glatiramer acetate injection site.
    Rubio Fernández D; Rodríguez Del Canto C; Marcos Galán V; Falcón N; Edreira H; Sevane Fernández L; Francoli Martínez P; Sánchez-De la Rosa R
    Adv Ther; 2012 Mar; 29(3):267-75. PubMed ID: 22382874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.